Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering in the U.S. on Friday.
BioProcess International reviews key biotech trends from the first half of 2026, including US onshoring, China's biologics ...
In a joint letter to Treasurer Jim Chalmers, 17 industry organisations called for consultation on two RDTI changes announced ...
An ever-evolving battlefield has plenty of lessons to teach ...
With a lifelong passion for baseball and love of science, Jake Bruml began his career in biotech but transitioned to direct ...
"Complex chemical processes are essential for making DNA." This long-held assumption in the field of biotechnology has been ...
The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...
What do Botox, rat poison, weight-loss drugs and a fictional murder investigation have in common? At the University of Nevada ...
Ipsen will buy U.S.-based Kartos Therapeutics for $450 million to expand its oncology pipeline with a late-stage blood ...
The work with Nvidia also focuses on the agentic guardrails required for the responsible and reliable deployment of AI in lab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results